ArticleScientific reports2025
FNA-Tg improves the diagnostic efficacy of FNAC for PTC lateral cervical LN metastasis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of relevant indicators in the diagnosis of cervical lymph node metastasis in papillary thyroid cancer.Frontiers in oncology · 2026Article
- Predictive value and clinical guidance of FNA-Tg combined with BRAF V600E for PTC cervical lymph node metastasis: a case report.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The detection of thyroglobulin in lymph node (LN) fine needle aspirates (FNA-Tg) is an effective supplement to ultrasound and fine needle aspiration cytology (FNAC) in diagnosis of cervical LN metastases for patients with papillary thyroid carcinoma (PTC). However, there is no unique cutoff value of FNA-Tg in practice. We aimed to determine the optimal cutoff of FNA-Tg and evaluate the interfering factors of FNA-Tg. A serial of 405 lateral cervical LN samples from 317 patients with PTC were analyzed retrospectively. Receiver operating characteristic (ROC) curve was used to determine the optimal cutoff of FNA-Tg. The factors that impact FNA-Tg were evaluated. Serum Tg, serum thyroglobulin antibody (TgAb) and serum thyroid stimulating hormone (TSH) level, and thyroid status did not differ between the malignant and benign LN groups. The median FNA-Tg was 3.81 ng/mL (0.16-33.40 ng/mL) in LNs without metastasis and 310.32 ng/mL (124.41-500.00 ng/mL) in LNs with metastasis, and the differences reached statistical significance (P < 0.01). The optimal cutoff of FNA-Tg was 36.22 ng/mL, and the values of area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) was 0.88, 0.89, 0.75, 0.91 and 0.71, respectively. The diagnostic accuracy of FNA-Tg cutoff of 36.22ng/mL was 85%. When FNAC and the present FNA-Tg cutoff of 36.22 ng/mL were combined together, the diagnostic sensitivity, specificity, PPV, NPV and diagnostic accuracy was 0.96, 0.75, 0.92, 0.87 and 91%, respectively. FNA-Tg improves the diagnostic efficacy of FNAC for PTC lateral cervical LN metastasis, and the optimal cutoff value of FNA-Tg was 36.22 ng/mL. FNA-Tg was affected by LN status but was not associated with serum Tg, serum TgAb, serum TSH and thyroid status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.